Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia

Abstract Background To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia. Methods The study consists of 180 patients, aged 40–75 years, with hyperlipidemia. All patients were...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrey Sivkov, Natalya Chernus, Roman Gorenkov, Sergey Sivkov, Svetlana Sivkova, Tamara Savina
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Cardiovascular diseases Hyperlipidemia Cholesterol Low-density lipoprotein Hydroxymethylglutaryl-CoA reductase inhibitors Pharmacogenetics Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/258ca855a46d4652a6af528e7261c8d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:258ca855a46d4652a6af528e7261c8d8
record_format	dspace
spelling	oai:doaj.org-article:258ca855a46d4652a6af528e7261c8d82021-11-14T12:39:50ZRelationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia10.1186/s12944-021-01586-71476-511Xhttps://doaj.org/article/258ca855a46d4652a6af528e7261c8d82021-11-01T00:00:00Zhttps://doi.org/10.1186/s12944-021-01586-7https://doaj.org/toc/1476-511XAbstract Background To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia. Methods The study consists of 180 patients, aged 40–75 years, with hyperlipidemia. All patients were divided into two equal groups: patients with different SLCO1B1 (521CC, 521CT and 521TT) and MDR1 (3435CC, 3435TC and 3435TT) genotypes. Each group was divided into rosuvastatin-treated, atorvastatin-treated and simvastatin-treated subgroups. The lipid-lowering effect of statins was assessed by tracing changes in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels. Results The use of statins over a 4-month period led to substantial reductions in TC and LDL-C levels. The hypolipidemic effect of studied agents was seen in both groups. However, it was less pronounced in patients with 521CC genotype. No statistically significantly differences were found between carriers of 3435TT, 3435CT and 3435CC genotypes. Conclusions The lipid-lowering efficacy of rosuvastatin was higher compared to other two statins. Patients with SLCO1B1 521CC genotype are more likely to encounter a decrease in the hypolipidemic effect of statins. Such a risk should be considered when treating this category of patients. MDR1 polymorphism had no significant effect on statin efficacy.Andrey SivkovNatalya ChernusRoman GorenkovSergey SivkovSvetlana SivkovaTamara SavinaBMCarticleCardiovascular diseasesHyperlipidemiaCholesterolLow-density lipoproteinHydroxymethylglutaryl-CoA reductase inhibitorsPharmacogeneticsNutritional diseases. Deficiency diseasesRC620-627ENLipids in Health and Disease, Vol 20, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cardiovascular diseases Hyperlipidemia Cholesterol Low-density lipoprotein Hydroxymethylglutaryl-CoA reductase inhibitors Pharmacogenetics Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	Cardiovascular diseases Hyperlipidemia Cholesterol Low-density lipoprotein Hydroxymethylglutaryl-CoA reductase inhibitors Pharmacogenetics Nutritional diseases. Deficiency diseases RC620-627 Andrey Sivkov Natalya Chernus Roman Gorenkov Sergey Sivkov Svetlana Sivkova Tamara Savina Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
description	Abstract Background To determine the effect of genetic polymorphism of drug transporters on the efficacy of treatment with Rosuvastatin, Atorvastatin and Simvastatin in patients with hyperlipidemia. Methods The study consists of 180 patients, aged 40–75 years, with hyperlipidemia. All patients were divided into two equal groups: patients with different SLCO1B1 (521CC, 521CT and 521TT) and MDR1 (3435CC, 3435TC and 3435TT) genotypes. Each group was divided into rosuvastatin-treated, atorvastatin-treated and simvastatin-treated subgroups. The lipid-lowering effect of statins was assessed by tracing changes in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels. Results The use of statins over a 4-month period led to substantial reductions in TC and LDL-C levels. The hypolipidemic effect of studied agents was seen in both groups. However, it was less pronounced in patients with 521CC genotype. No statistically significantly differences were found between carriers of 3435TT, 3435CT and 3435CC genotypes. Conclusions The lipid-lowering efficacy of rosuvastatin was higher compared to other two statins. Patients with SLCO1B1 521CC genotype are more likely to encounter a decrease in the hypolipidemic effect of statins. Such a risk should be considered when treating this category of patients. MDR1 polymorphism had no significant effect on statin efficacy.
format	article
author	Andrey Sivkov Natalya Chernus Roman Gorenkov Sergey Sivkov Svetlana Sivkova Tamara Savina
author_facet	Andrey Sivkov Natalya Chernus Roman Gorenkov Sergey Sivkov Svetlana Sivkova Tamara Savina
author_sort	Andrey Sivkov
title	Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
title_short	Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
title_full	Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
title_fullStr	Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
title_full_unstemmed	Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
title_sort	relationship between genetic polymorphism of drug transporters and the efficacy of rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
publisher	BMC
publishDate	2021
url	https://doaj.org/article/258ca855a46d4652a6af528e7261c8d8
work_keys_str_mv	AT andreysivkov relationshipbetweengeneticpolymorphismofdrugtransportersandtheefficacyofrosuvastatinatorvastatinandsimvastatininpatientswithhyperlipidemia AT natalyachernus relationshipbetweengeneticpolymorphismofdrugtransportersandtheefficacyofrosuvastatinatorvastatinandsimvastatininpatientswithhyperlipidemia AT romangorenkov relationshipbetweengeneticpolymorphismofdrugtransportersandtheefficacyofrosuvastatinatorvastatinandsimvastatininpatientswithhyperlipidemia AT sergeysivkov relationshipbetweengeneticpolymorphismofdrugtransportersandtheefficacyofrosuvastatinatorvastatinandsimvastatininpatientswithhyperlipidemia AT svetlanasivkova relationshipbetweengeneticpolymorphismofdrugtransportersandtheefficacyofrosuvastatinatorvastatinandsimvastatininpatientswithhyperlipidemia AT tamarasavina relationshipbetweengeneticpolymorphismofdrugtransportersandtheefficacyofrosuvastatinatorvastatinandsimvastatininpatientswithhyperlipidemia
_version_	1718429096702115840

Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia

Ejemplares similares